1. Home
  2. NCRA vs SNOA Comparison

NCRA vs SNOA Comparison

Compare NCRA & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.28

Market Cap

5.6M

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

N/A

Current Price

$2.41

Market Cap

6.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCRA
SNOA
Founded
2002
1999
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
6.1M
IPO Year
2022
2006

Fundamental Metrics

Financial Performance
Metric
NCRA
SNOA
Price
$0.28
$2.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
114.5K
9.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,288,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.19
52 Week Low
$0.31
$1.77
52 Week High
$2.40
$6.92

Technical Indicators

Market Signals
Indicator
NCRA
SNOA
Relative Strength Index (RSI) 33.41 35.19
Support Level N/A $2.30
Resistance Level $0.45 $3.85
Average True Range (ATR) 0.07 0.16
MACD 0.01 -0.02
Stochastic Oscillator 12.00 18.95

Price Performance

Historical Comparison
NCRA
SNOA

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: